Polyketide and Prenylxanthone Derivatives from the Endophytic Fungus Aspergillus sp. TJ23. Issue 12 (7th December 2018)

• Record Type: Journal Article
• Authors: Qiao, Yuben; Tu, Kun; Feng, Wenya; Liu, Junjun; Xu, Qianqian; Tao, Li; Zhu, Hucheng; Chen, Chunmei; Wang, Jianping; Xue, Yongbo; Zhang, Yonghui
• Is Part Of: Chemistry & biodiversity. Volume 15:Issue 12(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-12-07
• Subjects: Aspergillus -- polyketide, prenylxanthone -- ECD, cytotoxicity -- biological activity; Biochemistry -- Periodicals; Molecular biology -- Periodicals; Biodiversity -- Periodicals; 572
• DOI: 10.1002/cbdv.201800395
• Languages: English
• ISSNs: 1612-1872

Abstract

Abstract: Eight secondary metabolites, including a new polyketide, named asperetide (1 ) and a new prenylxanthone derivative, called asperanthone (4 ), and six known compounds, ( S )‐3‐butyl‐7‐methoxyphthalide (2 ), ruguloxanthone C (3 ), tajixanthone hydrate (5 ), tajixanthone methanoate (6 ), salimyxin B (7 ), and ergosterol (8 ), were isolated and identified from the medicinal plant‐derived fungus, Aspergillus sp. TJ23. The new structures and their absolute configurations were elucidated via multiple methods, including 1D‐ and 2D‐NMR, HR‐ESI‐MS, UV, IR, and the electronic circular dichroism (ECD) calculations. All of the isolates were characterized from the strain for the first time. The in vitro bioassay showed that compounds3–5 and8 exerted inhibitory activities against five cancer cell lines (B16, MDA‐MB‐231, 4T1, HepG2, and LLC) with IC50 values ranging from 5.13 to 36.8 μm . Abstract :